Biopharma Innovation Conference 2018
Join Us for our Session at BioPharma Innovation Conference 2018
About This EventIn collaboration with Illumina and a pharma partner, Q2 Solutions | EA Genomics has demonstrated technical feasibility for utilizing TruSight Tumor 170 Next Generation Sequencing (NGS) assay in the presence of UMIs to enable low frequency mutation detection (down to ~0.4%) in circulating-tumor DNA.
Please plan to join us on September 19th, 11:00 a.m., for our session, “Matched FFPE and ctDNA Analysis using Illumina TruSight Tumor 170 NGS Assay”, to learn more.
- Speaker: Stephanie Hastings, Ph.D., Scientist, Assay Development, Translational Genomics
- Location: Innovation Conference, Wyndham Grand Plaza Royale, 2288 Pudong Avenue, Shanghai, 200136, CN
We look forward to meeting you in Shanghai.
- Genomics Laboratories
- Biomarker Services
- Precision Medicine
- Companion Diagnostics
- Central Laboratories
Staff Scientist II, Assay Development, Translational Genomics
Stephanie B. Hastings, Ph.D., is a Staff Scientist II in Assay Development, Translational Genomics at Q2 Solutions | EA Genomics. In this role, she is responsible for the development and validation of genomic assays to support research and clinical programs. Stephanie is currently leading development efforts surrounding liquid biopsy applications as well as panel-based tumor mutational burden (TMB) next-generation sequencing (NGS) analyses.
Stephanie has more than 10 years of experience across diverse disciplines including: clinical molecular diagnostics, animal health vaccine development, genetic engineering and protein biochemistry.
Stephanie earned a Bachelors degree in Microbiology from North Carolina State University, followed by a Ph.D. in Biochemistry and Molecular Biology at the University of Georgia